After moving 16.1% during today's afternoon session, Evolus is now trading at a price of $10.53 per share. On average, analysts give it a target price of $16.56.
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States.
Potential Evolus Investors Should Analyze the Following:
-
Evolus has moved -18.7% over the last year.
-
The company has a price to earnings growth (PEG) ratio of -1.28. A number between 0 and 1 could mean that the market is undervaluing Evolus's estimated growth potential
-
Its Price to Book (P/B) ratio is 32.01
Understanding Evolus's Operating Margins
| Date Reported | Total Revenue ($ k) | Operating Expenses ($ k) | Operating Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2022-12-31 | 148,616 | 150,304 | -38.74 | 39.3 |
| 2021-12-31 | 99,673 | 119,754 | -63.82 | 47.47 |
| 2020-12-31 | 56,540 | 106,939 | -121.5 | 55.23 |
| 2019-12-31 | 34,925 | 121,698 | -271.4 | n/a |
Averaging out to -123.9% over the last 4 years, Evolus's operating margins also have a high coefficient of variability, which stands at 84.2%. On the other hand, we note that the firm's margins are growing at a 38.5% compounded average yearly rate.
